EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

BRAF mutations occur in 10–15% of colorectal cancers (CRCs) and confer adverse outcome. While RAF inhibitors such as vemurafenib (PLX4032) have proven effective in BRAF mutant melanoma, they are surprisingly ineffective in BRAF mutant CRCs, and the reason for this disparity remains unclear. Compared...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Corcoran, Ryan B., Ebi, Hiromichi, Turke, Alexa B., Coffee, Erin M., Nishino, Michiya, Cogdill, Alexandria P., Brown, Ronald D., Pelle, Patricia Della, Dias-Santagata, Dora, Hung, Kenneth E., Flaherty, Keith T., Piris, Adriano, Wargo, Jennifer A., Settleman, Jeffrey, Mino-Kenudson, Mari, Engelman, Jeffrey A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3308191/
https://ncbi.nlm.nih.gov/pubmed/22448344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-11-0341
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados